Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -2.22% 44.00 43.70 44.30 44.40 43.80 44.00 1,157,157 16:35:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 81.8 21.4 3.5 12.7 200

Ekf Diagnostics Share Discussion Threads

Showing 4076 to 4100 of 4525 messages
Chat Pages: Latest  169  168  167  166  165  164  163  162  161  160  159  158  Older
I note the excellent Trading Update this morning from Myhealthchecked (MHC).

From which I note the following excerpts -

Penny McCormick, Chief Executive Officer of MyHealthChecked Plc, said: "I am extremely proud of the hard work and adaptability of the MyHealthChecked team in 2021, which has enabled us to succeed in a highly competitive retail market and deliver to the pharmacy leaders. We believe that the strong commercial relationships that have been established in 2021 and include both of the UK's top pharmacy retailers will provide a solid foundation as we look to commercialise a wider range of tests in H1 2022.

"We have worked to harness the opportunity that the COVID testing market has provided for us and the earnings generated have created significant growth in the business which we will continue to build upon in 2022. While there is still market uncertainty about the future of COVID testing, we are set to reinvest our earnings into the delivery of our growing product pipeline in 2022, and I look forward to providing future updates to investors."

In terms of COVID testing, the above is just one example relating directly to the UK, but as I have alluded to previously, testing 'beyond' COVID looks set to materially expand, and I am expecting EKF to have exposure to that significant 'global' growth opportunity.

Staying with COVID testing, at least 'for now', recall that in March 2021 EKF signed a 'multiyear', multi-million dollar global supply contract with its partner from the private sector materially contributing to EKF's 2021 performance and importantly 'beyond'. The contract has an initial term of two years after which it renews automatically on a monthly basis, taking the initial term to March 2023 (more on this shortly). EKF has also broadened its customer base reducing reliance on this single customer.

Readers will no doubt get my drift regarding the existing and future opportunity that test kits and the related products are offering over both the medium term, and indeed 'beyond!

You are talking about the last few weeks whereas the question you're being asked is how do you account for the last 15 months or so. More specifically since 9 Nov 2020 when ekf came to a screeching halt. Ndx is more than +20% since (even after the recent wobbles) I don't need to tell you what ekf has done since do I. Discuss.
Legitimate question but our Wan has no answer on that.
Wan, I thank you for your extensive market info, but I think at this point it would be more useful to hear your take on the share price as of late. I’d like to hear opinions on why the price share is dipping in the face of record revenue and exceeded quarterly forecasts. What is going on?
Staying with testing beyond COVID-19, and in particular at-home collection.

Luke T. Daum, PhD, CSO at EKF. “I anticipate the market for home collection to expand exponentially. Novel at-home sample collection and stabilization kits containing optimized media that function beyond simple saline and PBS will be developed for a range of new diagnostic molecular tests.” -

Clinical Laboratories: 15 Industry Predictions for 2022

Prediction #4: Pharmacy-based and at-home testing will continue to grow and be widely accepted.

COVID has changed the testing dynamic, taking it out of traditional hospital or physician office venues, and into pharmacies and consumers’ homes. The experts see this trend continuing and even accelerating into 2022.

“The COVID pandemic opened the door to widespread use and acceptance of pharmacies as critical, convenient and rapid testing and vaccination centers,” notes Blum. The expansion of healthcare services by pharmacy clinics could be an opportunity for IVD companies to provide point-of-care, CLIA-waived tests for rapid, on-site testing at the clinics, and for local laboratories to partner with the pharmacies to provide more comprehensive and esoteric testing services.”

The range of tests available in the home, whether as prescription only test or without a prescription, will also continue to increase, further decentralizing the testing process.

“At-home collection has emerged from the current pandemic to become an important tool beyond COVID-19 detection. Traditionally, diagnostic tests need to be administered by a healthcare provider. At-home collection will allow users the flexibility to perform diagnostic testing from the comfort of the home. A few existing tests, like Cologuard require a prescription, but the at-home collection market will expand, and several exciting new tests will become available without a prescription and purchased online or over the counter,” says Luke T. Daum, PhD, CSO at EKF. “I anticipate the market for home collection to expand exponentially. Novel at-home sample collection and stabilization kits containing optimized media that function beyond simple saline and PBS will be developed for a range of new diagnostic molecular tests.”

Significantly, this trend is probably a genie-out-of-the-bottle moment in which at-home and other non-traditional forms of testing will not go away once the pandemic enters its endemic phase.

“COVID ushered in mobile, point-of-care and at-home diagnostics, along with the growth of telemedicine. These will continue to greatly impact the future of testing,” says Cha Roberts. “At-home diagnostics has made it easier, and more accessible for people to test and receive quick, accurate results. Moving forward, with high-sensitivity molecular tests, people will be able to test themselves, before they even start exhibiting symptoms, with high-sensitivity molecular tests.”

Decentralizing testing either in a neighborhood pharmacy or in a patient’s home will have benefits across the healthcare enterprise, predicts David Wilson, commercial director of diagnostics for Avacta Group plc.

“There is an increasing demand for more patient-centric healthcare, to not only deliver better clinical outcomes but also more cost-efficient healthcare solutions. For example, decentralized testing aims to bring testing out of the hospital laboratory and closer to the patient, and ultimately to point-of-care diagnostics and patient self-testing, to enable the delivery of healthcare where and when it is required,” says Wilson. “With faster turnarounds, test results will be delivered in clinically meaningful timeframes to truly inform clinical and treatment decisions, improving outcomes for patients. Presently, many tests done in the laboratory take time to process, and results are often returned after clinical decisions have already been made. Key applications would be in the rapid prescription of appropriate antibiotics, by quickly knowing that the pathogen is bacterial and its antimicrobial resistance profile, and in wider population screening for early detection of disease, which can make a huge difference in cancer outcomes.”

Further, decentralized testing will democratize the process, taking it out of the hands of specialists, Wilson predicts.

“This decentralized approach requires simple, accurate tests that require little specialist training to use—recent developments with COVID testing and the increased adoption of lateral flow tests for diagnosis, for example, have proven that the technologies are available to deliver these solutions,” he says. “The increased awareness and use of these diagnostics have also shown the capability of non-healthcare specialists to successfully run them. This will lay the groundwork for the adoption of decentralized testing for many other diseases, and potentially fuel the development of self-testing, to enable patients to take more control of their healthcare.”

Prediction #5: The menu of pathogen and genomic tests will increase.

Home testing will give birth to a growing menu of pathogen and genomic tests, according to Daum.

“I anticipate at-home testing to couple with ongoing advancements in molecular pathogen testing and genomic screening/susceptibility tests for cardiac, diabetes and cancer detection. I expect a growing ‘menu’ for biomarker and genomic-based tests in 2022. Users of at-home and over-the-counter tests will be able to monitor and manage chronic conditions before they emerge. The cost of long-read next-generation sequencing continues to become more cost efficient,” says Daum. “Thus, at-home genetic testing will expand in 2022 and beyond, opening attractive markets in bioinformatics where an individual’s genome, obtained from at-home collection can be stored and re-assessed prospectively as new genomics/genotyping tests are developed.”

Full article in digital magazine CLP 2022 Buyers Guide (EKF are included)- hTTp://

Pldazzle...The following article coincidentally came onto my radar this morning (I wasn't specifically looking for it). It discusses clinical trials and biomaterials delivery supply due to the pandemic and how the companies reacted, collaborated, and overcome the challenges, including being 'prepared' for the big restart in clinical trials (and future pandemics/variants). Interestingly, the volume of molecular transport medium used in clinical trials is hardly trivial.

I believe EKF may have also been working with Cenetron Diagnostics in response to the pandemic (and possibly prior to), so others may also find it interesting on a number of fronts -

Innovation in an Integrated and Robust Clinical Trials and Biomaterials Solution

18 January 2022


Brandon and Dan explain how an innovative, integrated and collaborative approach is crucial for the continued scale-up in advanced therapies, as well as lessons learned from interruptions to clinical trials and biomaterials delivery supply due to the pandemic.

How have clinical trials been affected by Covid-19, and what have you done or are you doing to overcome either exacerbated or novel challenges?

BH: If Covid-19 has taught us anything, it’s to expect the unexpected and just to be prepared. I think we saw a big shift in the way clinical trials were run during Covid-19 and there were lots of issues from the supply side, the FDA even issued some guidance about decentralising supply chain.

For clinical trials in general, we saw a shift from patients being seen at doctors’ offices to being seen at home. With a lot of home visits as opposed to doctor’s office visits, the supply chain supply chain was one of the biggest problems that we ran into.

More generally, the supplies that were needed for clinical trials or other projects changed drastically. For one client where we would usually manufacture 100,000 tubes of a molecular transport medium, we found ourselves manufacturing ~8 million from March/April 2020 through to January 2021. This was a huge scale up for us personnel-wise, manufacturing-wise, clinical trial-wise, trying to keep our staff safe.

We run a lot of oncology and infectious disease trials so we couldn’t not be in the office or the lab. We therefore had to find ways of doing this safely, and also pivoting our business model a little bit. For example, we were very clinical trial-heavy at one point and moved over to manufacturing when the clinical trial piece slowed down because they couldn’t see patients. So I think that the biggest change was trying to overcome staffing and really just supply chain in general.

How did you collaborate with people who were perhaps outside the typical or expected sphere of potential partners?

BH: During the project I described above, where we were manufacturing molecular transport medium cryovials, the vials that were typically used to store this medium weren’t available. They came from overseas, you couldn’t get them in, there were huge delays in having them manufactured and we saw Coca Cola step in to help with manufacturing. So if you can imagine their 20-ounce Coca Cola bottles before they were blown up into the actual bottle itself, these are called preforms. These were small tubes with great seals, and we were able to obtain millions of them so that they could be used for the testing of Covid-19.

Full interview - hTTps://

Thanks Wan
Pldazzle...Thanks for the update.

The low volume I was referring to was based on most trial sizes. However, I did no research on it, and what you reveal is indeed quite interesting, but to my knowledge (which is limited), there are more reagents involved in COVID PCR tests than just what EKF supply. Again, what this also demonstrates is that there is pent up demand for reagents 'beyond' COVID testing (COVID testing is not going to disappear). And it's important to point out that it's not just COVID-19 testing that requires phosphate-buffered saline (PBS), or viral transport media such as PrimeStore® MTM, with PCR testing for other infectious diseases e.g. RSV, flu A, flu B, HIV, TB and more, also requiring the same products to run tests. Indeed, PBS (and variations of it) is also being used as sample preparation to run other tests such as ELISA and lateral flow.

wan #2482.... Thanks. I gather the trial concerned addresses a potential $1bn market, so not peanuts. And a poster on the ADVFN AGL board quotes Jelenko on "the other site" as follows:
"The reagent that held up the ovarian is also used in the PCR covid test and as such there has been abnormal demand, the suppliers are limited because of the certification and quality control requirements for the labs that produce this so alternative suppliers are not found at the drop of a hat. I guess Angle's order was sequestered by PCR test providers. Apparently it is being sorted."

My "paradigm shift" comment/prediction in a previous post is gathering momentum. Watch this space!

Abbott, BD, Quidel pursue DTC strategies amid 'paradigm shift' for at-home, self-testing

The three test makers said at last week's J.P. Morgan conference they see opportunities for direct-to-consumer, digitally-connected testing for diseases beyond COVID-19.

Published Jan. 18, 2022

Abbott CEO Robert Ford said at last week's J.P. Morgan healthcare conference that the convergence of digital technology and medtech is creating "incredible opportunities to advance healthcare, change healthcare [and] change the way it's delivered."

Ford added that the company is specifically looking to "start to build a more sustainable rapid point-of-care, rapid diagnostic business not only that goes straight to the consumer, but also into other channels outside of the four walls of the hospital."

During Quidel's presentation at the J.P. Morgan conference, CEO Doug Bryant said digital health is "something that we don't talk a great deal about but, nevertheless, we have been spending a great deal of time on it."

Bryant noted that Quidel's integrated digital health and diagnostics products currently are focused on the enterprise and employee health markets. Still, the company is looking for near-term opportunities to expand into the consumer use market beyond COVID-19.

"We have to demonstrate that individuals can collect [specimens] properly and that will be very helpful in clinical trials where we try to demonstrate the sensitivity and specificity necessary to meet the FDA's hurdles for OTC products," the CEO said. "That's very much on the forefront of our minds and is something we're working on."

The goal is to empower consumers to take charge of their own health and wellness by decentralizing testing through investment in digital health, according to Bryant. Quidel is developing a self-test module for cell phones, called QVue, to report results in near real-time.

"A paradigm shift has occurred from the public," Bryant said "Now, with COVID, it has changed the way people think [about self-testing]."

Full story - hTTps://

Pldazzle...Ultimately, I wouldn't know whether such reagents referred to are manufactured by EKF, or more to the point could be manufactured, or indeed whether on their own (relatively low volume?) such reagents would be of any interest.

Importantly though, what it does highlight, is that having a reliable supply chain 'partner' like EKF, is paramount. In this regard, the implementation of EKF's growth plan and indeed the acquisition of ADL, has added further to that attraction in my view.

wan and other experts ... a question for you. Apart from EKF I also hold shares in AGL, which last week gave the following update on (inter alia) a major ovarian cancer study involving two of the company's platforms and for which [positive] results had been hoped for in H2/21:

"... While good progress has been made in many areas of the ovarian cancer study, there have been some third-party supply chain difficulties attributed to COVID-19. A key supplier has been unable to deliver certain reagents as scheduled. Completion of the study sample analysis depends on these reagents and the situation is being closely managed. Consequently, headline results for the study are now expected in H1 2022."

Is there any reason to suppose there might be anything of direct or indirect interest in this for EKF, either before or after today's announcement?

Good to have the debate since it crops up here regularly.

Thanks Cambridge - good points. You still leave out a third possibility though (as in your first scenario may not go far enough). Forgive me for insisting in that I think I did answer the question. Let me try another angle. You say lots of good news have failed to move the market since 80p level. On the face of it it looks indeed so. However, another key lesson of history is that when markets fail to react to seemingly bullish/bearish news then the odds are quite high the market is about to turn bearish/bullish. We get this "unintuitive" market behaviour the whole time (example - markets starting to rally strongly in April 2020 at the very start of covid fears with 99% of market participants not trusting it for MONTHS until it became obvious to everyone) as markets never top/bottom on bad/good news but quite the reverse. This kind of behaviour is a key property of financial markets. If so, then one should be afraid of a major leg south for ekf shares (a third possibility you have left out). Will it happen, I hear you say? No one knows at this stage as the market is being range bound but one best prepare for all eventualities.As far as I am concerned, I am prepared to go long or short depending on market's next move. Flexibility is the name of the game - all I have to do is patiently wait for odds stacking in one's favour (up or down). Have learned ago never to have ego in this game and alway be keen to bend with the market. Whichever way one cuts it, money can only be made by being in sync with the market. Been long and short ekf several times over the last two years (my last one being a failed long truth be told). In my view, all fundamental reasoning in the world is not worth the paper it is written on unless the market validates it. If he does, I will be the first to review my skepticism and go long (again).
I'm afraid that argument cambridgedon is based on price anchoring. I'm long here but all the highly rated growth shares in my portfolio and watchlist have been derated over the past few months. Try being a shareholder in GAW for example! At some point sentiment will shift back in favour of long dated investments such as growth stocks but for now, the market is more interested in value plays. Simple as that I think.

I have no problem with most of that: however, it doesn't completely answer the question. The market valued EKF at over 80p back in September last year. Since then lots of good things have been announced and testing (thought by many to be a flash in the pan) shows no signs of falling off anytime soon.
So, we are left with only two conclusions: 1) the price got well ahead of itself last year or 2)It's undervalued now.
Which is it?

CambridgeIn one sentence: it is all in the price. I have been making this point since late Oct/early Nov 2020 as one's job (if we want to make money of course) is to get in sync with Mr Market not to play macho with him (deep down everyone knows who loses that game). A key lesson of history is that markets proceed fundamentals (Paul Tudor Jones has elaborated much better than I can on this one) not the other way around. If you really think about it, this one is one of the key reasons why 99% find this game so difficult to crack. It also explains why Wan has been waiting for a very long time to will the market (into submission on back of his never changing thesis) and it is too late for him to change his mind now (this is where ego plays against one - after all who likes to be wrong?) Been doing this for a good while and in my opinion there are only two catalysts that move shares: a. meaningful fundamental surprises (strictly defined as those that are accompanied by "immediate and meaningful" price moves ONLY not what random people think such a surprise are) and b.major shifts in market perceptions (watch out when every single board member is bullish / bearish - in such circumstances it doesn't take much for inflection points to introduce themselves which also quickly help shifting perceptions the other way. George Soros termed the above as reflexivity in that price alone contains a lot of fundamental information which goes unnoticed by most market participants.
I also note Sourcebio's Trading Update today reporting excellent growth and that their full year results will be significantly ahead of market expectations, and that their core divisions are all now back to pre-Covid levels of trading and all are poised to accelerate their growth.

Which also aligns with other diagnostic players recently reporting/guiding that their core businesses are back to pre-Covid levels of trading (and above) and are also poised to further accelerate growth.


Why do YOU think Mr M (to use your preferred idiom) isn't convinced EKF is worth more?

Good for you - for all your inflexibility and excitement, the market is not voting in favour of your thesis. Quite funny you never ask the question why. Conviction is the enemy of truth - flexibility sets one free in this (very counterintuitive and) hyper competitive game.
I am excited by todays news regarding EKF's strategic partnership agreement with Yourgene Health plc. With additional tests already being indicated for deployment within the largest healthcare market in the world, I believe that we are witnessing the early stages of what will become a major platform for expansion and growth.

In my view, EKF is likely, in one form or another, to also include expansion into the direct-to-consumer sample collection and testing market (beyond the existing COVID-19 sample collection and testing). The growth opportunity on offer will align with my previous comment (and indeed that of Quidel's CEO, Douglas Bryant) regarding a new era of diagnostics, where people are empowered to understand their own health in the comfort and privacy of their homes, and is likely to represent a paradigm shift, in turn offering a very large global growth opportunity for non-COVID related products.

Today'a announcement illustrates the strategy of acquiring ADL delivering results
Thank you wan

Last year the EoY TS was on 12-Jan. I do like it when companies either pre-announce the timing of their TSs or at least manage a bit of consistency on their timing. In that context, hopefully we will see it next week.

Shanklin...EKF has already guided in the Half Year Report that the Board is very confident that trading for the year ending 31 December 2021 will be comfortably ahead of already materially upgraded management expectations. So, I don't see any reasons to expect anything other than the outperformance for the year being realised.

We usually get a Trading Update in January for the Year End 31st Dec, which may also include an indication regarding the 1st quarter outlook.

Given that testing demand has been reported elsewhere as being very strong (unfortunately), it bodes well for both the final and first quarters in my view.

Wan - while you're at it (and since share price has been totally out of sync with your views for a long time) any idea how long before physicists fully understand the strange world of quantum physics?
Chat Pages: Latest  169  168  167  166  165  164  163  162  161  160  159  158  Older
Your Recent History
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20221206 00:59:00